Cyclotherapy: opening a therapeutic window in cancer treatment.
about
Persistence to anti-cancer treatments in the stationary to proliferating transition.Diffuse large B-cell lymphoma with combined TP53 mutation and MIR34A methylation: Another "double hit" lymphoma with very poor outcome?Combinatorial inhibition of Plk1 and PKCβ in cancer cells with different p53 statusCharacteristics and survival of patients with advanced cancer and p53 mutations.Cancer therapy. Targeting the poison within.Sodium dichloroacetate exhibits anti-leukemic activity in B-chronic lymphocytic leukemia (B-CLL) and synergizes with the p53 activator Nutlin-3.Array-based genome-wide RNAi screening to identify shRNAs that enhance p53-related apoptosis in human cancer cellsSuppression of eukaryotic initiation factor 4E prevents chemotherapy-induced alopeciaAmifostine alleviates radiation-induced lethal small bowel damage via promotion of 14-3-3σ-mediated nuclear p53 accumulationTreatment-induced cell cycle kinetics dictate tumor response to chemotherapyHigh cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects.Integrated experimental and simulation study of the response to sequential treatment with erlotinib and gemcitabine in pancreatic cancer.AKT mediates actinomycin D-induced p53 expression.Battle of the eternal rivals: restoring functional p53 and inhibiting Polo-like kinase 1 as cancer therapy.Revisiting p53 for cancer-specific chemo- and radiotherapy: ten years after.Silencing of Dicer1 temporally separates pro- and anti-apoptotic signaling and confers susceptibility to chemotherapy in p53 mutated cells.Silencing of CDK2, but not CDK1, separates mitogenic from anti-apoptotic signaling, sensitizing p53 defective cells for synthetic lethality.Inhibition of post-transcriptional steps in ribosome biogenesis confers cytoprotection against chemotherapeutic agents in a p53-dependent manner.The use of the NEDD8 inhibitor MLN4924 (Pevonedistat) in a cyclotherapy approach to protect wild-type p53 cells from MLN4924 induced toxicity.p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance.
P2860
Q30834504-63803772-9FBE-49DB-94E7-5C2F6A31001EQ33688416-FE31D224-13FA-4000-B548-63479205AA85Q33688600-08B7AEBF-4594-429A-A258-8280991CD9E6Q33977102-3550CC2C-AF56-4518-916F-2CFA5AB0C282Q34028512-9A62FA35-04A7-4E9B-9A03-A38CFBDB1AE3Q34100963-C71A5B7D-4FAA-4D90-A32A-3C9513C13273Q34365770-CBEFB6EA-4170-4D03-8267-D20ED56EC792Q34479333-C982203E-E379-4C40-A489-A0B17D1FD968Q34654628-7A47D9D4-008B-465D-BC84-8A9C036EBFFDQ35740145-81A22B6C-B825-4554-9DEC-1842AEBDE5AFQ37031262-DE05CAEF-95BF-4829-82E4-E45B26C81411Q37085804-0D59F8E2-21B3-45EE-AA2D-CEF61E4451B5Q37718441-97DADD6E-E035-4398-8A5B-EEF78EA17A27Q38129174-1D9B3D5B-3927-4371-96E9-970BE79B12D2Q38187890-B8BD3771-47F3-49D9-ACCC-D571E37F0B61Q38993174-DE0DFF59-2F3F-458B-BA5D-BEE3539B8EA7Q39199216-51DB82EA-346D-4B1E-AFA1-02643B8E609CQ41489855-C17724F8-CB7F-4411-82E9-5B6981ACA344Q42361441-059BE8F8-AB31-4C2D-8BD7-ACE149664DB7Q42362115-F4085A0C-FB30-4393-A69D-1FBF6C2C1AC2
P2860
Cyclotherapy: opening a therapeutic window in cancer treatment.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Cyclotherapy: opening a therapeutic window in cancer treatment.
@en
Cyclotherapy: opening a therapeutic window in cancer treatment.
@nl
type
label
Cyclotherapy: opening a therapeutic window in cancer treatment.
@en
Cyclotherapy: opening a therapeutic window in cancer treatment.
@nl
prefLabel
Cyclotherapy: opening a therapeutic window in cancer treatment.
@en
Cyclotherapy: opening a therapeutic window in cancer treatment.
@nl
P2860
P356
P1433
P1476
Cyclotherapy: opening a therapeutic window in cancer treatment.
@en
P2093
Ingeborg M M van Leeuwen
P2860
P304
P356
10.18632/ONCOTARGET.524
P407
P577
2012-06-01T00:00:00Z